MedTrace Logo

Study of MT-5111 in HER2-positive Solid Tumors

NCT04029922 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2023-06-18

No results posted yet for this study

Summary

This will be a Phase 1b, first in human, open-label, dose escalation and expansion study of MT-5111 (a recombinant fusion protein) given as monotherapy in subjects with HER2-positive solid tumors

Conditions

  • HER2-positive Solid Cancers

Interventions

DRUG

MT-5111 (experimental study drug)

Experimental treatment with MT-5111

Sponsors & Collaborators

  • Molecular Templates, Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-12
Primary Completion
2023-02-01
Completion
2023-04-27
FDA Drug
Yes

Countries

  • United States
  • Australia
  • New Zealand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04029922 on ClinicalTrials.gov